Big Pharma Diabetes Face-Off

While many GLP-1 drugs for the treatment for type 2 diabetes are currently available, this continues to be an attractive disease target for many of the biggest pharmaceutical players. Bristol-Myers Squibb (NYSE: BMY  ) and AstraZeneca (NYSE: AZN  ) market the GLP-1 agonists Byetta and Bydureon, and Novo Nordisk's  (NYSE: NVO  )  Victoza is a leader in this specific class of drugs.

But wait -- it looks like another big pharma player is poised to enter this space. GlaxoSmithKline (NYSE: GSK  ) put its drug albiglutide forward for approval from the Food and Drug Administration last Monday and, pending approval, could grab part of this market. In this video, health care analysts Max Macaluso and David Williamson discuss what investors need to consider in this race to dominate the diabetes market.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2204688, ~/Articles/ArticleHandler.aspx, 4/16/2014 7:24:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement